| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-11-09 | vantictumab (anti-Fzd7, OMP-18R5) | non-small cell lung cancer (NSCLC) | preclinical | OncoMed Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2015-11-09 | navicixizumab - anti-DLL4/VEGF bispecific (OMP-305B83) | preclinical | OncoMed Pharmaceuticals (USA - CA) | Cancer - Oncology | |
| 2015-11-09 | interleukin-18 binding protein (IL-18BP) | systemic inflammation | AB2 Bio (Switzerland) | Inflammatory diseases | |
| 2015-11-08 | sarilumab (REGN88/SAR153191) | rheumatoid arthritis | 3 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2015-11-08 | GLPG0634 (filgotinib) | rheumatoid arthritis | 2b | Galapagos (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2015-11-07 | Soliris® (eculizumab) | atypical hemolytic uremic syndrome (aHUS) | Alexion Pharmaceuticals (USA - CT) | Rare diseases - Kidney diseases | |
| 2015-11-07 | enoblituzumab (MGA271) | cancers expressing B7-H3 in the tumor and/or tumor-associated vasculature | 1 | Macrogenics (USA - MD) | Cancer - Oncology |
| 2015-11-06 | AFM21 and AFM22 (NK- and T-cell TandAbs generated against EGFRvIII) | preclinical | Affimed (Germany) | Autoimmune diseases | |
| 2015-11-06 | MI130004 | HER2-expressing tumors | preclinical | PharmaMar (Spain) | Cancer - Oncology |
| 2015-11-06 | triheptanoin (UX007) | Glut1 DS - Encephalopathy due to GLUT1 deficiency | 3 | Ultragenyx Pharmaceutical (USA - CA) | Rare diseases - CNS diseases - Neurological diseases |
| 2015-11-06 | BI 695501 (biosimilar version of Humira® (adalimumab)) | 1 | Boehringer Ingelheim (Germany) | Autoimmune diseases – Dermatological diseases - Inflammatory diseases - Rheumatic diseases | |
| 2015-11-05 | RXI-109 | prevention of the progression of retinal scarring in patients with advanced neovascular age-related macular degeneration | 1-2 | RXi Pharmaceuticals (USA - MA) | Ophtalmological diseases |
| 2015-11-05 | ABT-555 | relapsing forms of multiple sclerosis (RFMS) | 1 | Abbvie (USA - IL) | Neurodegenerative diseases |
| 2015-11-05 | Paclical® (paclitaxel) | metastatic breast cancer | Oasmia Pharmaceutical (Sweden) | Cancer - Oncology | |
| 2015-11-05 | UCART19 | refractory relapsed Acute Lymphoblastic Leukemia (ALL) following mismatched allogeneic stem cell transplantation | Cellectis (France) Great Ormond Street Hospital (GOSH) (UK) University College London (UCL) (UK) | Cancer - Oncology | |
| 2015-11-04 | BioChaperone® Combo | type 1 diabetes, type 2 diabetes | 1b | Adocia (France) | Metabolic diseases |
| 2015-11-04 | Acucela (USA - MA) | Ophtalmological diseases | |||
| 2015-11-04 | Charcot-Marie-Tooth disease type 2D (CMT2D) | Atyr Pharma (USA - CA) | Rare diseases - Genetic diseases - Neurological diseases | ||
| 2015-11-03 | Debio 1143 | squamous non-small cell lung cancer (NSCLC), platinum-refractory ovarian cancer, basal-like/claudin low triple negative breast cancer | 1 | Debiopharm (Switzerland) | Cancer - Oncology |
| 2015-11-03 | LY3127804 | advanced solid tumors | 1 | Eli Lilly (USA - IN) | Cancer - Oncology |
